Initially identified in cutaneous melanoma, where it was first characterized, PRAME has since been detected in numerous other tumor types, such as leukemia, neuroblastoma, non-small-cell lung cancer (NSCLC), breast cancer, ovarian cancer, and several sarcomas [22,35,36]. This evidence concerns the gene PRAME and cutaneous melanoma.